CAR-T Cell Therapy(Unicar-Therapy)

N/A

Report date: 2024/12/20 16:41:36

Base Information

Drug NameCAR-T Cell Therapy(Unicar-Therapy)
Drug Alias NameChimeric Antigen Receptor T-cell Therapy(Unicar-Therapy)
ClassificationCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLymphoma, B-CellHematopoietic stem cell transplantation (HSCT)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A